Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.38 |
| ▸ | PPARA | Q07869 | 8/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | LDHB | P07195 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676894 | 0.88 | LDHA (0.40) | PPARGPPARAMAOAPTPN1PTPN11 | |
| SCHEMBL5678150 | 0.84 | ALOX5 (0.37) | PPARGPPARAMAOAPTPN1PTPN11 | |
| SCHEMBL5678457 | 0.82 | ALOX5 (0.39) | PPARGPPARAPTPN1LDHALDHB | |
| SCHEMBL5676726 | 0.81 | LDHA (0.43) | PPARGPPARAMAOAPTPN1PTPN11 | |
| SCHEMBL5676132 | 0.80 | LDHA (0.42) | PPARGPPARAMAOAPTPN1PTPN11 | |
| SCHEMBL5586851 | 0.79 | PPARA (0.41) | PPARGPPARAPTPN1PTPN11LDHA | |
| SCHEMBL5680235 | 0.79 | PRKCI (0.41) | PPARGPPARAMAOAPTPN1PTPN11 | |
| SCHEMBL5676682 | 0.79 | MAOA (0.40) | MAOAPTPN1LDHALDHBNPSR1 | |
| SCHEMBL5677054 | 0.79 | NPC1 (0.37) | PPARGPPARAPTPN1PTPN11LDHA | |
| SCHEMBL5680671 | 0.79 | ALOX5 (0.38) | PPARGPPARAMAOAPTPN1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | PPARG 3732/4885PPARA 3398/4885MAOA 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.